Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics of the Leiden EAC cohort

From: IL2RA is associated with persistence of rheumatoid arthritis

  Total (n = 645) DMARD-free sustained remission achieved during follow-up (n = 119) DMARD-free sustained remission not achieved during follow-up (n = 526)
Baseline    
 Age (years), mean (SD) 56.9 (15.6) 58.8 (16.9) 56.5 (15.3)
 Female, n (%) 430 (66.7) 74 (62.2) 356 (67.7)
 Symptom duration (weeks), median (IQR) 18.8 (10.3–37.3) 12.9 (7.3–28.6) 20.3 (11.4–40.0)
 Swollen joint count in 66 joints, median (IQR) 8 (4–13) 9 (4–15) 8 (4–13)
 CRP level (mg/l), median (IQR) 18 (8–42) 18 (8–43) 18 (7–37)
 ACPA-positive, n (%) 332 (52.5) 15 (13.0) 317 (61.3)
 RF-positive, n (%) 371 (57.8) 32 (27.1) 339 (64.7)
Follow-up    
 Duration until DMARD-free sustained remission (years), median (IQR)   4.3 (2.9–6.1) N/A
  1. ACPA anti-citrullinated peptide antibodies, CRP C-reactive protein, DMARD disease-modifying antirheumatic drug, EAC Early Arthritis Clinic, IQR interquartile range, N/A not applicable, RF rheumatoid factor, SD standard deviation
  2. Data were missing on swollen joint count in seven patients, on CRP level in 29 patients, on ACPA in 13 patients, on RF in three patients, and on symptom duration in 47 patients
  3. The median symptom duration and the frequencies of ACPA-positivity and RF-positivity were significantly different between patients who achieved and did not achieve DMARD-free sustained remission during follow-up (all p <0.001). The other baseline characteristics did not differ between the groups